DIPROMONProject reference: 306157
Funded under :
"Multimodular biomarker analysis workflow for diagnosis, prognosis and monitoring of drug treatment response in bladder cancer"
Total cost:EUR 4 596 144,2
EU contribution:EUR 3 492 216,5
Coordinated in:United Kingdom
Topic(s):HEALTH.2012.1.2-1 - Development of technologies with a view to patient group stratification for personalised medicine applications
Call for proposal:FP7-HEALTH-2012-INNOVATION-1See other projects for this call
Funding scheme:CP-FP - Small or medium-scale focused research project
"With the advent of Omics technologies capable of profiling substantial fractions of molecular entities from the genome down to the metabolome level a significant boost in understanding disease pathophysiology, consequently providing tailored diagnostics and therapy, was expected. With impressive results for selected diseases, cancer still sees significant shortcomings. One reason for this clinical situation is certainly the apparent heterogeneity of cancers, manifesting in clinical presentation and outcome, but also on the personalized molecular level.
Within DIPROMON we selected bladder cancer as a prototypical example for the need of personalization efforts in therapy, and we plan of using this clinically highly challenging disease phenotype for establishing a general workflow for enabling personalization strategies towards rational decision on tailoring therapeutic interventions for defined patient groups. DIPROMON on its basis follows a computational Systems Biology approach for delineating statistical rules for patient segmentation, resting on patient-specific biomarker profiles interpreted in tight integration with patient-specific clinical data. DIPROMON will establish a workflow including quality control aspects for i) selecting biomarker panels for given clinical phenotypes, ii) providing modular instrumentation for measuring the profiles in a clinical setting, and iii) deriving statistics-driven rules for patient segmentation regarding optimal therapy. DIPROMON will finally validate the concept in bladder cancer."
EU contribution: EUR 704 168,5
GU2 7XH GUILDFORD
Tel.: +44 1483 683498
Fax: +44 1483 689567
EU contribution: EUR 370 602
GERSTHOFER STRASSE 29-31
EU contribution: EUR 356 694
DONAU CITY STRASSE 1 TECH GATE VIENNA
EU contribution: EUR 520 700
RUE DU MAIL 34
Tel.: +336 83 09 99 15
EU contribution: EUR 896 984